Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FKBP1A | P62942 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3584401 | 0.85 | FKBP1A (0.36) | FKBP1ABRD4CYP3A4MAPTMAPK1 | |
| SCHEMBL3589569 | 0.82 | FKBP1A (0.39) | FKBP1ABRD4CYP3A4MAPTMAPK1 | |
| SCHEMBL3586977 | 0.65 | CYP3A4 (0.34) | FKBP1ABRD4SLC6A3CYP3A4MAPT | |
| SCHEMBL11997296 | 0.65 | BRD4 (0.63) | FKBP1ABRD4ALDH1A1SMN1; SMN2 | |
| SCHEMBL3586980 | 0.65 | ALDH1A1 (0.35) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL10749202 | 0.63 | FKBP1A (0.44) | FKBP1ABRD4CYP3A4MAPTMAPK1 | |
| SCHEMBL13146444 | 0.62 | BRD4 (0.46) | FKBP1ABRD4CYP3A4MAPTSMN1; SMN2 | |
| SCHEMBL29306521 | 0.62 | CYP3A4 (0.45) | FKBP1ABRD4CYP3A4MAPTMAPK1 | |
| SCHEMBL27425673 | 0.62 | FKBP1A (0.52) | FKBP1ABRD4CYP3A4MAPTMAPK1 | |
| SCHEMBL28208165 | 0.62 | BRD4 (0.35) | BRD4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7728028-B2 | Substituted imidazoline compounds | GRUENENTHAL GMBH (DE) | 2010-06-01 | — | — | US | disclosed |
| US-20090048323-A1 | SUBSTITUTED IMIDAZOLINE COMPOUNDS | GRUENENTHAL GMBH (DE) | 2009-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048323-A1 | SUBSTITUTED IMIDAZOLINE COMPOUNDS | ITCH, OPRK1, ALDH1A1 | FKBP1A 1151/4885BRD4 1230/4885SLC6A3 247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.